Company announced positive clinical study results showing 81.8% of patients achieved cellulite improvement with their combined treatment approach. The publication of peer-reviewed data in Aesthetic Surgery Journal Open Forum, along with objective imaging confirmation and histological evidence of tissue remodeling, demonstrates efficacy of their Renuvion® product and supports market positioning in the aesthetic surgery space.
The company received expanded FDA clearance for an advanced capability on its flagship AYON system, which enhances its competitive positioning as an all-in-one platform. The planned limited commercial launch demonstrates confidence in the product, and the addition of power liposuction is expected to drive greater market demand. Q1 2026 results showed 36% growth in the Surgical Aesthetics segment with raised FY2026 revenue guidance.
Articles that tag APYX but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
